| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ― | ― | ― | ― | ― | ― | |
46 Neutral | C$17.52M | -2.70 | ― | ― | -100.00% | -8.70% | |
44 Neutral | C$5.29M | -0.95 | -148.48% | ― | -46.59% | 8.26% | |
44 Neutral | C$15.39M | -2.93 | ― | ― | 15.64% | 58.47% | |
43 Neutral | C$6.59M | -3.63 | ― | ― | -100.00% | -192.62% | |
39 Underperform | C$6.28M | -0.58 | -664.21% | ― | ― | -80.42% | |
38 Underperform | C$4.87M | -1.11 | -271.33% | ― | 15.95% | -1.81% |
Ayurcann Holdings Corp. reported Q1 2026 sales of $14,638,697, maintaining a strong presence in the Canadian cannabis market. The company is recognized as a top vape producer in Ontario, with a 5% share of the national vape market. Despite a decrease in gross profit margin from 40% to 26% compared to the previous year, Ayurcann continues to expand its product offerings and retail presence, launching 30 new stock keeping units in the past six months. This strategic growth in product categories like vapes, pre-rolls, and concentrates positions Ayurcann as a trusted national supplier, enhancing its market leadership and operational efficiency.
Ayurcann Holdings Corp. reported record gross revenue of $55,446,352 for the fiscal year ending June 30, 2025, marking a 21% increase from the previous year. The company has expanded its product portfolio to 80 SKUs nationwide and continues to focus on innovation and operational efficiency. Despite competitive pressures, Ayurcann has successfully increased its market share and brand loyalty, and plans to delist from the OTCQB while continuing to trade on the Canadian Securities Exchange.